HomeCompareVXTRQ vs ABBV

VXTRQ vs ABBV: Dividend Comparison 2026

VXTRQ yields 6666666.67% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VXTRQ wins by $8.25873857526507e+44M in total portfolio value
10 years
VXTRQ
VXTRQ
● Live price
6666666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.25873857526507e+44M
Annual income
$825,849,488,962,360,000,000,000,000,000,000,000,000,000,000,000,000.00
Full VXTRQ calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — VXTRQ vs ABBV

📍 VXTRQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVXTRQABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VXTRQ + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VXTRQ pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VXTRQ
Annual income on $10K today (after 15% tax)
$566,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$701,972,065,618,006,100,000,000,000,000,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, VXTRQ beats the other by $701,972,065,618,006,100,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VXTRQ + ABBV for your $10,000?

VXTRQ: 50%ABBV: 50%
100% ABBV50/50100% VXTRQ
Portfolio after 10yr
$4.129369287632535e+44M
Annual income
$412,924,744,481,180,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

VXTRQ
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VXTRQ buys
0
ABBV buys
0
No recent congressional trades found for VXTRQ or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVXTRQABBV
Forward yield6666666.67%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$8.25873857526507e+44M$102.3K
Annual income after 10y$825,849,488,962,360,000,000,000,000,000,000,000,000,000,000,000,000.00$24,771.77
Total dividends collected$8.258722632802889e+44M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VXTRQ vs ABBV ($10,000, DRIP)

YearVXTRQ PortfolioVXTRQ Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$666,677,367$666,666,666.67$11,550$430.00+$666.67MVXTRQ
2$41,538,243,978,220$41,537,530,633,437.17$13,472$627.96+$41538243.96MVXTRQ
3$2,418,785,178,923,619,000$2,418,740,733,002,562,000.00$15,906$926.08+$2418785178923.60MVXTRQ
4$131,632,535,180,835,430,000,000$131,629,947,080,693,970,000,000.00$19,071$1,382.55+$131632535180835424.00MVXTRQ
5$6,694,929,569,421,761,000,000,000,000$6,694,788,722,609,116,000,000,000,000.00$23,302$2,095.81+$6.69492956942176e+21MVXTRQ
6$318,233,313,948,923,370,000,000,000,000,000$318,226,150,374,284,100,000,000,000,000,000.00$29,150$3,237.93+$3.1823331394892335e+26MVXTRQ
7$14,137,160,116,927,522,000,000,000,000,000,000,000$14,136,819,607,281,600,000,000,000,000,000,000,000.00$37,536$5,121.41+$1.4137160116927522e+31MVXTRQ
8$586,942,647,681,175,100,000,000,000,000,000,000,000,000$586,927,520,919,850,000,000,000,000,000,000,000,000,000.00$50,079$8,338.38+$5.8694264768117504e+35MVXTRQ
9$22,774,359,015,829,920,000,000,000,000,000,000,000,000,000,000$22,773,730,987,196,898,000,000,000,000,000,000,000,000,000,000.00$69,753$14,065.80+$2.277435901582992e+40MVXTRQ
10$825,873,857,526,507,000,000,000,000,000,000,000,000,000,000,000,000$825,849,488,962,360,000,000,000,000,000,000,000,000,000,000,000,000.00$102,337$24,771.77+$8.25873857526507e+44MVXTRQ

VXTRQ vs ABBV: Complete Analysis 2026

VXTRQStock

Voxtur Analytics Corp. operates as a real estate technology company in the United States and Canada. The company offers ReboGateWay Pro, a live format for automatic property updates and alerts on changes within farms/lists; Title Toolbox, a tool that provides property data in a live format for automatic property updates and alerts; Investor Toolbox, an access to all property and farming tools; Lender Toolbox provides targeted data to pinpoint homeowners to exact lending program criteria for various lending options; Premier Lists, a custom data list service designed to create prospect list for a specific area; TaxExpress, a tax certificate solution; and O and E QuickCheck, a data intelligence report for real estate that evaluate loans or portfolios and close, Voxtur Verify and Data Connect. It also provides Anow SaaS Appraiser product, tool for appraisers and analysts to manage valuation orders, employees, scheduling, accounting, client communication, and reporting; Voxtur Direct, an appraisal management solution; and Reports Now, an automated report builder. In addition, the company offers AOL, a full-coverage title alternative; residential and commercial services; default to manage loan portfolio; insured title products that protect purchasers and lenders against defects in title; and uninsured title products. Further, it provides Real Property Tax Analytics for transparency and insight; ApexSketch, a line of software applications designed to build floorplan sketches; ApexSketch Portal which allow users to save Property Sketch Data; GeoViewport to aggregate visual property data into one location; StreetScape, a visual and data intelligence product; Apex Professional Services; consulting practice focused on property assessment; and technology-enabled solutions related to property tax. The company is based in London, Canada.

Full VXTRQ Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this VXTRQ vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VXTRQ vs SCHDVXTRQ vs JEPIVXTRQ vs OVXTRQ vs KOVXTRQ vs MAINVXTRQ vs JNJVXTRQ vs MRKVXTRQ vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.